Indutrade signs agreement to acquire all shares in Medexa Diagnostisk Service

Indutrade (STO:INDTB) today signed an agreement to acquire all of the shares in Medexa Diagnostisk Service AB, with annual sales of approximately SEK 25 million.

Medexa specialises in high-end technology for healthcare with a focus on foetal surveillance and ultrasound applications. Customers consist primarily of county councils and private clinics.

Indutrade takes possession of the company today, and it will be part of the Industrial Components business area. The acquisition is expected to have a marginally positive impact on Indutrade's earnings per share.

Since 2008, annual sales in Indutrade's medical technology segment have grown from approximately SEK 60 million to approximately SEK 400 million.

Stockholm, 8 October 2013

INDUTRADE AB (publ)

About Indutrade

Indutrade markets and sells components, systems and services with a high-tech content within selected niches. Indutrade's business is distinguished by

- high-tech products for recurring needs

- growth through a structured and tried-and tested acquisition strategy

- a decentralised organisation characterised by an entrepreneurial spirit.

The Group is organised into five business areas: Engineering & Equipment, Flow Technology, Fluids & Mechanical Solutions, Industrial Components and Special Products. Indutrade's sales totalled SEK 8,384 million in 2012, generating operating income of SEK 905 million before depreciation of intangible assets. Indutrade is listed on the Nasdaq OMX Stockholm.

Source:

Indutrade 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Radnet’s DeepHealth and HOPPR forge partnership to advance AI in healthcare